The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 23: 3106 - 3110

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.23.014

Drugs and Clinic Practice

Efficacy and safety of anlotinib monotherapy and combinated therapy in the treatment of advanced pheochromocytoma/paraganglioma

  • Xianda CHEN ,
  • Nan MA ,
  • Shengjie GUO ,
  • Zhenhua LIU ,
  • Kai. YAO
Expand
  • Sun Yat?sen University Cancer Center，State Key Laboratory of Oncology in South China，Guangdong Provincial Clinical Research Center for Cancer，Guangzhou 510060，China

Received date: 2023-09-14

  Online published: 2024-01-08

Fold

Abstract

Objective To evaluate the efficacy and safety of anlotinib monotherapy and combined therapy in patients with advanced pheochromocytoma/paraganglioma. Methods Nine patients with advanced pheochromocytoma/paraganglioma （PPGL） who were admitted to the Department of Urology， Sun Yat-sen University Cancer Center from January 2018 to June 2023 were collected. Patients were divided into four groups according to different treatments： anlotinib monotherapy group （3 patients）， anlotinib combined with PD-1 monoclonal antibody immunotherapy group （3 patients）， anlotinib combined with immunotherapy and chemotherapy group （2 patients）， and anlotinib combined with chemotherapy group （1 patients）. The effectiveness and safety of different treatment regiments of anlotinib were analyzed. Results Objective response rate （ORR） ： （44%）， Partial response（PR）： （44%）， Stable disease（SD）： （44%）， Progressive disease（PD）： （11%）， Disease control rate （DCR）： （89%）. The ORR of 2 patients with SDH gene mutation， SDHB and SDHD respectively， was 100%. Median overall survival time（OS） was 16.3 months （IQR： 11.3 ~ 21.8 months）. Median progression-free survival （PFS） was 16.3 months （IQR： 9.8 ~ 20.8 months）. There were 2 patients with adverse events grade ≥ 3/4， all of which were hypertension. Conclusions Anlotinib monotherapy and combined therapy have preliminary efficacy and manageable safety in the treatment of advanced pheochromocytoma/paraganglioma.

Key words： anlotinib; pheochromocytoma; paraganglioma; efficacy; safety

Cite this article

Xianda CHEN , Nan MA , Shengjie GUO , Zhenhua LIU , Kai. YAO . Efficacy and safety of anlotinib monotherapy and combinated therapy in the treatment of advanced pheochromocytoma/paraganglioma[J]. The Journal of Practical Medicine, 2023 , 39(23) : 3106 -3110 . DOI: 10.3969/j.issn.1006-5725.2023.23.014

References

1 李卓然，来东，贾玉琪，等. 嗜铬细胞瘤术后复发因素的单中心分析［J］. 微创泌尿外科杂志， 2022，11（6）：372-376.
2 JASIM S， JIMENEZ C. Metastatic pheochromocytoma and paraganglioma： Management of endocrine manifestations， surgery and ablative procedures， and systemic therapies ［J］. Best Pract Res Clin Endocrinol Metab， 2020，34（2）：101354.
3 周亚琼，严鹏，张华敏，等. 腹部副神经节瘤的临床特征及长期预后分析［J］. 实用医学杂志， 2021，37（21）：2743-2747.
4 王庭俊，谢良地. 《嗜铬细胞瘤和副神经节瘤诊断治疗专家共识（2020版）》解读［J］.中华高血压杂志， 2021，29（8）：708-714.
5 WANG Z， LIU F， LI C， et al. Case Report： Octreotide plus CVD chemotherapy for the treatment of multiple metastatic paragangliomas after double resection for functional bladder paraganglioma and urothelial papilloma ［J］. Front Oncol， 2023， 12：1072361.
6 JIMENEZ C， XU G， VARGHESE J， et al. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas： an American， Contemporary， Pragmatic Approach ［J］. Curr Oncol Rep， 2022，24（1）：89-98.
7 ZHANG X， WAKABAYASHI H， HIROMASA T， et al. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma［J］. Semin Nucl Med， 2023，53（4）：503-516.
8 FASSNACHT M， ASSIE G， BAUDIN E， et al. Adrenocortical carcinomas and malignant phaeochromocytomas： ESMO-EURACAN Clinical Practice Guidelines for diagnosis， treatment and follow-up ［J］ . Ann Oncol， 2020， 31（11）：1476-1490.
9 JIAO Q， BI L， REN Y， et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance［J］. Mol Cancer，2018，17（1）：36.
10 WANG K， CRONA J， BEUSCHLEIN F， et al. Targeted Therapies in Pheochromocytoma and Paraganglioma ［J］. J Clin Endocrinol Metab， 2022，107（11）：2963-2972.
11 ZHOU Y， CUI Y， ZHANG D， et al. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas ［J］. J Clin Endocrinol Metab， 2023，108（3）：755-766.
12 HELM J， DRUKEWITZ S， POSER I， et al. Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia： A New Pseudohypoxic In Vitro Model ［J］. Cells， 2022，11（3）：560.
13 ILANCHEZHIAN M， JHA A， PACAK K， et al. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma ［J］. Curr Treat Options Oncol， 2020，21（11）：85.
14 PENG S， ZHANG J， TAN X，et al. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma ［J］. Front Endocrinol （Lausanne）， 2020，11：586857.
15 ZHOU A P， BAI Y， SONG Y， et al. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma： A Randomized Phase Ⅱ Clinical Trial ［J］. Oncologist， 2019， 24（8）：e702-e708.
16 LIN J， FANG Q， ZHENG X. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China ［J］. PLoS One， 2023，18（2）：e0281402.
17 NAING A， MERIC-BERNSTAM F， STEPHEN B， et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers［J］. J Immunother Cancer， 2020， 8（1）：e000347.
18 FAN P， QIANG H， LIU Z，et al. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy ［J］. Front Immunol， 2022，13：937924.
19 胡浪，林小玲，唐文军. 呋喹替尼单药及联合PD-1抑制剂用于晚期转移性结肠癌后线治疗的疗效及安全性［J］. 实用医学杂志， 2023，39（15）：1966-1973.
20 KUDO M. Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma ［J］. Liver Cancer， 2020，9（6）：629-639.
21 HAN C， YE S， HU C， et al. Clinical Activity and Safety of Penpulimab （Anti-PD-1） With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma： An Open-Label， Multicenter， Phase Ib/II Trial （AK105-203） ［J］ . Front Oncol， 2021，11：684867.
22 ZHANG X， ZENG L， LI Y， et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer： a real-world retrospective study in China ［J］. Cancer Immunol Immunother， 2021，70（9）：2517-2528.
23 王玲燕，郭群依，王官良，等. 帕博利珠单抗联合安罗替尼治疗恶性嗜铬细胞瘤1例［J］. 江苏医药， 2022，48（8）：862-864.
24 O'KANE G M， EZZAT S， JOSHUA A M， et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma： the SNIPP trial ［J］. Br J Cancer， 2019，120（12）：1113-1119.
25 WANG Y， LIU B， LI F， et al. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma［J］. Front Endocrinol （Lausanne）， 2023，14：1274239.
26 FISHBEIN L， DEL RIVERO J， ELSE T， et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma ［J］. Pancreas， 2021， 50（4）：469-493.
27 NIEMEIJER N D， ALBLAS G， VAN HULSTEIJN L T， et al. Chemotherapy with cyclophosphamide， vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma： systematic review and meta-analysis ［J］. Clin Endocrinol （Oxf），2014，81（5）：642-651.
28 LIGON J A， SUNDBY R T， WEDEKIND M F， et al. A Phase ⅡTrial of Guadecitabine in Children and Adults with SDH-Deficient GIST， Pheochromocytoma， Paraganglioma， and HLRCC-Associated Renal Cell Carcinoma ［J］. Clin Cancer Res， 2023，29（2）：341-348.
Options
Outlines

/

〈 〉